reproxalap
Small molecule
Evidence outlook · regulatory review
Dry Eye Disease: FDA issued a complete response letter (2026-03-16)
FDA issues third complete response letter for reproxalap in dry eye disease. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.
Latest reported trial: NCT06493604 · Phase 3 · met primary endpoint · grade pending
Also in development:Allergic Conjunctivitis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06424444 NCT06424444 · Dry Eye Disease Result from Aldeyra's press release of 5 May 2025 (Form 8-K Exhibit 99.2), which names no trial number. The link to NCT06424444 rests on design and timing: it is the only Aldeyra reproxalap dry eye field trial completed in 2024 to 2025 (421 participants, primary completion 3 November 2024). Registry: NCT06424444 | 3 | Subject-reported ocular discomfort score over Week 1 to Week 6 2024-11-03 | Ocular discomfort, Week 1 to Week 6 (field trial): numerically favoured reproxalap but not statistically significant vs vehicle; no figures released | not yet graded | link ↗ |
View 1 more trial
NCT06493604 NCT06493604 · Dry Eye Disease Registry: NCT06493604 | 3 | Ocular discomfort symptom score over 100 minutes in the dry eye chamber at Visit 1 and Visit 3 (Day -14 to Day 2) 2025-02-27 | Chamber trial, reproxalap vs vehicle (58 vs 58): ocular discomfort score difference -6.5 (95% CI -10.5 to -2.5), P=0.002. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Allergic Conjunctivitis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Reproxalap: this drug | Phase 3 | Small molecule | Reactive aldehyde species (RASP) | Partial signal | Featured results are non-efficacy only in this race | |
| Dexamethasone (Dextenza) | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Freneslerbart / Mevonlerbart | Phase 3 | Monoclonal antibody | Fel d 1 (major cat allergen protein) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent